Search Results
Mar 17, 2026, 16:00 ET High Tide Reports First Quarter 2026 Financial Results Featuring Record Revenue Exceeding $700 Million Annualized
dividing gross profit by revenue.iii.Operating expense is a non-IFRS measure and includes
More news about: High Tide Inc.
Mar 17, 2026, 14:35 ET Bitmine Immersion Technologies (BMNR) Công Bố Nắm Giữ 4,596 Triệu Token ETH và Tổng Cộng 11,5 Tỷ USD Tiền Mã Hóa và Tiền Mặt
Bitmine hiện vẫn được hỗ trợ bởi một nhóm các nhà đầu tư tổ chức hàng đầu như Cathie Wood của ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital và nhà đầu tư cá nhân Thomas "Tom" Lee nhằm giúp BitMine đạt mục tiêu sở hữu 5% ETHLAS
More news about: Bitmine Immersion Technologies, Inc.
Mar 17, 2026, 14:32 ET Bitmine Immersion Technologies (BMNR) Umumkan Kepemilikan ETH Mencapai 4,596 Juta Token dan Total Kepemilikan Kripto Maupun Total Uang Tunai Sebesar $11,5 Miliar
Bitmine tetap didukung oleh kelompok penting beranggotakan investor institusi seperti Cathie Wood dari ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital, dan investor pribadi Thomas "Tom" Lee guna mendukung tujuan Bitmine untuk mengakuisisi 5% ETH
More news about: Bitmine Immersion Technologies, Inc.
Mar 17, 2026, 14:26 ET Bitmine Immersion Technologies (BMNR) annonce que ses avoirs en ETH atteignent 4,596 millions de tokens, et que ses avoirs en crypto-monnaie et en liquidités atteignent 11,5 milliards de dollars
Bitmine est toujours soutenu par un groupe d'investisseurs institutionnels de premier plan, dont Cathie Wood d'ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital et l'investisseur privé Thomas « Tom » Lee, pour soutenir l'objectif de Bitmine visant à acquérir 5 % du nombre
More news about: Bitmine Immersion Technologies, Inc.
Mar 17, 2026, 10:13 ET NIH-Funded Randomized Clinical Trial Evaluating Weekly BRIXADI® for Opioid Use Disorder in Pregnancy and 12-months Postpartum Published in JAMA Internal Medicine
solution for injection. WARNINGS AND PRECAUTIONS Addiction, Abuse, and Misuse: BRIXADI contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Buprenorphine is sought by people with opioid use disorder and is subject
More news about: Braeburn
Mar 17, 2026, 10:01 ET Epidermolysis Bullosa Market Set for Significant Upswing During the Forecast Period (2025-2034) Amid Rising Therapeutic Advancements | DelveInsight
every two months via intravenous infusion and aims to improve skin lesions, lower overall disease burden, and prevent ongoing tissue damage. A Phase III clinical trial is currently underway in the United States and Europe, with top-line data expected in late 2025 and a European marketing authorization
More news about: DelveInsight Business Research, LLP
Mar 17, 2026, 10:00 ET New York Jets Become First NFL Team to Adopt Image-Streaming Technology for their Official Photography
the 1968 season, the team made history by becoming the first AFL franchise to win a world championship, defeating the Baltimore Colts in Super Bowl III – a victory widely credited with validating the AFL ahead of its 1970 merger with the NFL. Today, as one of the league's flagship franchises in the nation's
More news about: New York Jets
Mar 17, 2026, 09:19 ET TIAA Teams Up with Chicago Scholars to Invest in Chicago's Future at the 2026 Big Ten Men's Basketball Tournament
income. This figure represents all annuity income, including guaranteed and additional amounts, for all of TIAA's annuity products.iii As of December 31, 2025, assets under management across Nuveen Investments affiliates and TIAA investment management teams are $1.506 billion.
More news about: TIAA
Mar 17, 2026, 09:01 ET Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal
changing from surveillance to targeted radiotherapy.Co-PSMA trial data, combined with Phase II COBRA and anticipated results from a pivotal Phase III AMPLIFY study, are intended to be submitted to the United States (US) Food and Drug Administration (FDA) for a market authorisation of 64Cu-SAR-bisPSMA
More news about: Clarity Pharmaceuticals
Mar 17, 2026, 09:00 ET RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm
decrease in annualized fracture rates or otherwise the Phase III Orbit and Cosmic studies were much less likely to be able to demonstrate such a link than management claimed. On December 29, 2025, Ultragenyx announced that both its Phase III Orbit and Cosmic Studies had not "achieved statistical significance
More news about: The Gross Law Firm
Mar 17, 2026, 09:00 ET ENPH Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Enphase Energy, Inc. Securities Lawsuit -- The Gross Law Firm
its ability to manage its channel inventory; (ii) Enphase overstated its ability to mitigate effects arising from the termination of the 25D Credit; (iii) accordingly, Enphase overstated its financial and operational prospects; and (iv) as a result, the Company's public statements were materially false
More news about: The Gross Law Firm
Mar 17, 2026, 09:00 ET BYND Shareholder Alert: Beyond Meat, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm
material, non-cash impairment charge; (ii) the foregoing was likely to impair Beyond Meat's ability to timely file its periodic filings with the SEC; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times.DEADLINE: March 24, 2026 Shareholders
More news about: The Gross Law Firm
Mar 17, 2026, 09:00 ET NKTR Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in Nektar Therapeutics Securities Class Action Lawsuit -- The Gross Law Firm
applicable instructions and protocol standards; (ii) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial's results; (iii) accordingly, the REZOLVE-AA trial's overall integrity and prospects were overstated; and (iv) as a result, defendants' public statements were materially
More news about: The Gross Law Firm
Mar 17, 2026, 09:00 ET PLUG Shareholder Alert: April 3, 2026 Lead Plaintiff Deadline in Plug Power Inc. Securities Class Action Lawsuit -- The Gross Law Firm
facilities necessary to receive those funds; (ii) as such, Plug Power was likely to pivot toward more modest projects with less commercial upside; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.DEADLINE: April 3, 2026 Shareholders
More news about: The Gross Law Firm
Mar 17, 2026, 09:00 ET INO Shareholder Alert: April 7, 2026 Lead Plaintiff Deadline in Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit -- The Gross Law Firm
device was deficient; (ii) accordingly, Inovio was unlikely to submit it's lead product candidate, INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's
More news about: The Gross Law Firm
Mar 17, 2026, 09:00 ET LAKE Shareholder Alert: Lakeland Industries, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm
these businesses on Lakeland's financial results, as well as the overall strength and quality of Pacific Helmets' and Jolly's respective operations; (iii) Lakeland's business and financial results were significantly deteriorating because of, inter alia, tariff-related headwinds and timing, certification
More news about: The Gross Law Firm
Mar 17, 2026, 09:00 ET Seasats Quickfish USV Completes Continuous Eight-Day Sea Trial
an $89M SBIR Phase III award to support USMC USV efforts, and in 2026 the company announced
More news about: Seasats
Mar 17, 2026, 09:00 ET CWH Shareholder Alert: May 11, 2026 Lead Plaintiff Deadline in Camping World Holdings, Inc. Securities Class Action Lawsuit -- The Gross Law Firm
optimize profit using "data analytics;" (ii) the Company overstated the retail demand of consumers it was experiencing and/or reasonably expected; (iii) as a result, the Company would require "strict, corrective inventory management objectives," negatively impacting gross profit and margins; (iv) the
More news about: The Gross Law Firm
Mar 17, 2026, 08:30 ET Broad AD/PD™ 2026 Validation Reinforces ALZpath pTau217 Antibody as Industry Benchmark for Blood-Based Alzheimer's Diagnosis
Traveller master pre–screener study update: broadening recruitment into Trontier 1 and 2, phase III studies in early symptomatic AD - Presenter: Christopher Lane, Roche"The breadth of data presented featuring pTau217 highlights
More news about: ALZpath, Inc.
Mar 17, 2026, 08:30 ET IceCure Reports 2025 Full Year Financial & Operational Results
patients within 36 months across 30 clinical sites in the U.S. which can be used commercially.On March 16, 2026, the Company submitted a Class III amendment application to Health Canada seeking to expand its current regulatory approval to include the use of the ProSense® cryoablation system for
More news about: IceCure Medical
Mar 17, 2026, 07:57 ET Einride Partners With Texas Highway Operator to Create Autonomous Freight Testbed
[email protected] Merger Corp. IIIEric RosenfeldChief SPAC Officer Legato Merger Corp. III [email protected] This
More news about: Einride
Mar 17, 2026, 07:53 ET Einride Partners With Texas Highway Operator to Create Autonomous Freight Testbed
[email protected] Merger Corp. IIIEric RosenfeldChief SPAC Officer Legato Merger Corp. III [email protected] This
More news about: Einride
Mar 17, 2026, 07:52 ET Jaguar Uranium Initiates Rare Earth Element Assessment at Colombia's Berlin Project
initial multi-commodity resource estimate across the Berlin Project, subject to additional work, verification and regulatory requirements.III. By-Product Economics and Cost Structure — REE potential, including vanadium, nickel, phosphate, molybdenum, rhenium, and zinc may, if ultimately
More news about: Jaguar Uranium
Mar 17, 2026, 07:09 ET Lucid Ungkapkan Rincian Mobil Midsize yang Akan Datang dan Umumkan Aliran Pendapatan Rutin yang Baru Serta Menguraikan Langkah Disiplin Menuju Skala yang Menguntungkan
ii) efisiensi yang luar biasa dalam hal rekayasa dan produksi untuk memangkas biaya material, termasuk baterai, tenaga kerja, dan intensitas modal; iii) diversifikasi pendapatan, termasuk perangkat lunak, layanan, lisensi platform, kemitraan robotaxi, dan otonomi; dan (iv) kemitraan yang hemat modal,
More news about: Lucid Group
Mar 17, 2026, 06:50 ET Lucid、次期ミッドサイズ・プラットフォームの詳細を発表し、新たな経常収益源を公表 - 収益性の高い規模拡大への規律ある道筋を提示
Gravityのさらなる規模拡大、グローバルな事業展開の拡大、ソフトウェア製品とサービスの推進、材料コストと製造効率の取り組みの加速に注力する一方で、フリー・キャッシュ・フローの黒字化への道を短縮するために厳格な資本配分規律を維持します。Lucidはこの移行を支える主要な推進要素として、以下の項目を概説しました：i) 対応可能市場と固定費吸収を大幅に拡大するためのミッドサイズ・プラットフォームの規模拡大。ii) バッテリー、労務、資本集約度を含む部品コストを削減するためのエンジニアリングと製造における抜本的な効率化。iii) ソフトウェア、サービス、プラットフォーム・ライセンス、ロボタクシー・パートナーシップ、自動運転を含む収益の多様化。iv) 特にロボタクシーとプラットフォーム・ライセンスにおける資本効率の高いパートナーシップ。LucidのCFOであるTaoufiq
More news about: Lucid Group